Evidence map›Paper›PMID 30806568›Full record

ReviewNanomedicine (London, England)2019

Nanoparticle systems for cancer vaccine.

Ru Wen, Afoma C Umeano, Yi Kou, Jian Xu, Ammad Ahmad Farooqi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nanomedicine (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ru WenDepartment of Chemistry, University of Georgia, Athens, GA 30602, USA.
Afoma C UmeanoDepartment of Molecular & Cellular Pharmacology, University of Miami, Miller School of Medicine, Miami, FL 33136, USA.
Yi KouDepartment of Molecular & Computational Biology, University of Southern California, Los Angeles, CA 90089, USA.
Jian XuLaboratory of Cancer Biology & Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Ammad Ahmad FarooqiInstitute of Biomedical and Genetic Engineering (IBGE), Islamabad, 54000, Pakistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As effective tools for public health, vaccines prevent disease by priming the body's adaptive and innate immune responses against an infection. Due to advances in understanding cancers and their relationship with the immune system, there is a growing interest in priming host immune defenses for a targeted and complete antitumor response. Nanoparticle systems have shown to be promising tools for effective antigen delivery as vaccines and/or for potentiating immune response as adjuvants. Here, we highlight relevant physiological processes involved in vaccine delivery, review recent advances in the use of nanoparticle systems for vaccines and discuss pertinent challenges to viably translate nanoparticle-based vaccines and adjuvants for public use.

Indexed as

AnimalsCancer VaccinesDrug Delivery SystemsHumansNanoparticlesNanotechnologyCancer Vaccinesantigen deliverycancer vaccinedelivery systemsnanoparticlenanotechnologynanovaccine

Identifiers

PMID30806568
PMCPMC6439506

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.